Portola Pharma Cmn (PTLA) 20.86 $PTLA
Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXXA-4(TM) Study of Factor Xa Inhibitor Antidote AndexXa(TM) (andexanet alfa) in Patients with Acute Major Bleeding
GlobeNewswire - Tue Aug 30, 3:18AM CDT
--AndexXa Rapidly Reversed Anticoagulant Effect of Factor Xa Inhibitors; Excellent or Good Hemostasis Was Achieved in 79 Percent of Patients Over 12 Hours--
PTLA: 20.86 (+0.50)
Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA(TM)-4 Study of AndexXa(TM) (andexanet alfa) at European Society of Cardiology 2016 Congress
GlobeNewswire - Fri Aug 26, 7:00AM CDT
Portola Pharmaceuticals Inc. (Nasdaq
TLA) today announced that interim results from its ongoing Phase 3b/4 ANNEXA(TM)-4 trial of AndexXa(TM) (andexanet alfa), a Factor Xa inhibitor antidote, will be featured in an oral Late-Breaking Science Hot Line session at the European Society of Cardiology (ESC) 2016 Congress, which will take place from August 27-31 in Rome. The data also will be featured in the ESC's Hot Line - Preventive Strategies II press conference on Tuesday, August 30, at 9:00 a.m. CEST.
PTLA: 20.86 (+0.50)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.93 (+0.37), BIIB: 306.03 (+0.40), PTLA: 20.86 (+0.50), CLVS: 23.59 (-1.18), GILD: 77.42 (-0.96), ALXN: 125.63 (-0.23), REGN: 393.40 (+0.85)
Portola IndexXa's Regulatory Application Validated in the EU
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 6:48AM CDT
Portola (PTLA) announced that the European Medicines Agency has accepted to review the company's Marketing Authorization Application for IndexXa.
PTLA: 20.86 (+0.50), ANIP: 61.42 (+1.68), ANIK: 47.94 (+0.70)
Portola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa(TM) (andexanet alfa), a Factor Xa Inhibitor Antidote
GlobeNewswire - Fri Aug 19, 7:30AM CDT
Portola Pharmaceuticals Inc. (NASDAQTLA) today announced that the MAA for IndexXa(TM) (andexanet alfa; trade name in the United States is AndexXa(TM)), a Factor Xa inhibitor antidote, has been submitted to the EMA, completed the validation period, and has been accepted for review. IndexXa is in development for patients treated with a Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding and for patients requiring urgent or emergency surgery. Portola is seeking conditional approval of IndexXa in the EU through the centralized procedure. With the acceptance of the application, the EMA's Committee for Medicinal Products for Human Use (CHMP) will now begin the centralized review procedure under a standard 210-day review period.
PTLA: 20.86 (+0.50)
Portola (PTLA) Stock Down on CRL for AndexXa BLA in U.S.
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:16AM CDT
Portola (PTLA) received a Complete Response Letter for AndexXa (andexanet alfa) in the U.S.
PTLA: 20.86 (+0.50), ANIP: 61.42 (+1.68), GERN: 2.73 (+0.04), ANIK: 47.94 (+0.70)
Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa(TM) (andexanet alfa)
GlobeNewswire - Wed Aug 17, 9:56PM CDT
Portola Pharmaceuticals Inc. (NASDAQTLA) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for AndexXa(TM) (andexanet alfa). An FDA-designated Breakthrough Therapy, AndexXa is in development for patients treated with a direct (apixaban, rivaroxaban, or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Currently, there is no FDA-approved antidote for Factor Xa inhibitors.
PTLA: 20.86 (+0.50)
Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue Aug 09, 3:07PM CDT
Portola Pharmaceuticals Inc. (NASDAQTLA) today provided a corporate update and reported its financial results for the quarter ended June 30, 2016.
PTLA: 20.86 (+0.50)
Portola Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Tuesday, August 9
GlobeNewswire - Tue Aug 02, 3:07PM CDT
Portola Pharmaceuticals, Inc. (NasdaqTLA) announced today that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2016, and provide a general business overview on Tuesday, August 9, 2016, at 4:30 p.m. ET (1:30 p.m. PT).
PTLA: 20.86 (+0.50)
Biotechnology Stocks on Investors' Radar -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Tue Aug 02, 9:02AM CDT
The Biotech stocks are showing substantial strength as on Monday, August 01st, 2016, the NYSE Arca Biotechnology Index was up 2.7%, reaching a seven-month intra-day high. Stock-Callers.com now assesses the following equities and see how they fared at the last close: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by downloading their comprehensive and free reports at:
TRVN: 6.77 (-0.01), PTLA: 20.86 (+0.50), ANTH: 2.91 (+0.03), NERV: 12.35 (+0.13)
Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Wed Jun 22, 7:20AM CDT
On Tuesday, June 21, 2016, the NASDAQ Composite ended the trading session at 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% to finish at 17,829.73; and the S&P 500 closed at 2,088.90, up 0.27%. The gains were broad based as five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by accessing their free trade alerts at:
TRVN: 6.77 (-0.01), PTLA: 20.86 (+0.50), ANTH: 2.91 (+0.03), NERV: 12.35 (+0.13)
Corridor Company Case Study Examines Portola Pharmaceuticals' Use of Corridor's CLM Product in Managing All Aspects of Portola's Contract Management Process
PRWeb - Wed Jun 22, 2:48AM CDT
Corridor Company, Inc., the leading provider of contract lifecycle management software powered by the SharePoint and Office 365 platforms, has published a case study about the successful deployment of its Contract Management Business Application for SharePoint, CM[.app], by Portola Pharmaceuticals, a biopharmaceutical company with a foundation of products and product candidates that significantly advances patient care in the areas of thrombosis, other hematologic disorders and inflammation. Portola's legal and finance teams now use Corridor's software to manage their entire contract lifecycle, including contract creation and request, negotiation with external parties, documented approval, and metadata reporting.
PTLA: 20.86 (+0.50)
Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Portola Pharmaceuticals Inc. (NASDAQTLA), today announced that it recently dosed the first patient in a Phase 2a study that is evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell and T-cell malignancies who have failed multiple therapies. Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies.
PTLA: 20.86 (+0.50)
Portola Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference
GlobeNewswire - Tue May 31, 3:05PM CDT
Portola Pharmaceuticals (NasdaqTLA) today announced that Bill Lis, chief executive officer, will present at the Goldman Sachs 37 Annual Healthcare Conference on Tuesday, June 7, 2016, at 1:20 p.m. Pacific Time in Rancho Palos Verdes, Calif.
PTLA: 20.86 (+0.50)
Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
GlobeNewswire - Fri May 27, 7:45AM CDT
--Company Plans to Submit NDA and MAA for Betrixaban in Second Half of 2016--
PTLA: 20.86 (+0.50)
Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa(TM) (andexanet alfa) at International Society on Thrombosis and Haemostasis (ISTH) 2016 Scientific and Standardization Committee Meeting
GlobeNewswire - Mon May 23, 7:00AM CDT
Portola Pharmaceuticals Inc. (NASDAQTLA) today announced that the full data set from the Phase 3 APEX Study of betrixaban will be featured in an oral session at the 62nd Annual Scientific and Standardization Committee (SSC) Meeting of the International Society on Thrombosis and Haemostasis (ISTH), which will take place from May 25-28 in Montpellier, France. Additionally, new data from pharmacokinetic and mechanism of action studies of the Company's Factor Xa inhibitor antidote AndexXa (andexanet alfa) will be presented in poster sessions.
PTLA: 20.86 (+0.50)
How are Investors Treating These Biotech? - Portola Pharma, Vitae Pharma, Anthera Pharma, and Intra-Cellular Therapies
PR Newswire - Thu May 19, 7:35AM CDT
There is no saying when exactly the Biotech space will fully recover given the relentless pressures in pricing and lack in consumer confidence. One thing is for sure in the investors circle though - numerous opportunities are up for grabs but this industry requires due-diligence. Ahead of today's session, ActiveWallSt.com's presents four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Intra-Cellular Therapies Inc. (NASDAQ: ITCI). Receive your complimentary alerts on these stocks by signing up today at:
PTLA: 20.86 (+0.50), ANTH: 2.91 (+0.03), VTAE: 6.84 (-0.07), ITCI: 40.63 (+0.29)
Portola Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Thu May 05, 3:06PM CDT
Portola Pharmaceuticals Inc. (NASDAQTLA), today provided a corporate update and reported its financial results for the first quarter ended March 31, 2016.
PTLA: 20.86 (+0.50)
Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Thu Apr 14, 7:00AM CDT
Portola Pharmaceuticals (NasdaqTLA) today announced that new data from a pharmacokinetic modeling study designed to identify the dose of cerdulatinib for expansion cohorts in a Phase 2 study will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2016, which is taking place from April 16-20 in New Orleans.
PTLA: 20.86 (+0.50)
3 Biotech Takeover Targets That Could Get Bought Soon
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 13, 2:39PM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Biotech stocks have been especially hard hit over the past six months because of concerns over drug prices, and the sell-off within the industry has resulted in bargains that big pharma might find compelling. Among...
MDVN: 80.93 (+0.37), BMRN: 95.19 (+1.30), PTLA: 20.86 (+0.50), KITE: 58.87 (+1.25), AMGN: 170.13 (+0.07), BMY: 56.76 (-0.63)
Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXXA-4(TM) Study of Factor Xa Inhibitor Antidote AndexXa(TM) (andexanet alfa) in Patients with Acute Major Bleeding
GlobeNewswire - Tue Aug 30, 3:18AM CDT
--AndexXa Rapidly Reversed Anticoagulant Effect of Factor Xa Inhibitors; Excellent or Good Hemostasis Was Achieved in 79 Percent of Patients Over 12 Hours--
PTLA: 20.86 (+0.50)
Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA(TM)-4 Study of AndexXa(TM) (andexanet alfa) at European Society of Cardiology 2016 Congress
GlobeNewswire - Fri Aug 26, 7:00AM CDT
Portola Pharmaceuticals Inc. (Nasdaq
TLA) today announced that interim results from its ongoing Phase 3b/4 ANNEXA(TM)-4 trial of AndexXa(TM) (andexanet alfa), a Factor Xa inhibitor antidote, will be featured in an oral Late-Breaking Science Hot Line session at the European Society of Cardiology (ESC) 2016 Congress, which will take place from August 27-31 in Rome. The data also will be featured in the ESC's Hot Line - Preventive Strategies II press conference on Tuesday, August 30, at 9:00 a.m. CEST. PTLA: 20.86 (+0.50)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.93 (+0.37), BIIB: 306.03 (+0.40), PTLA: 20.86 (+0.50), CLVS: 23.59 (-1.18), GILD: 77.42 (-0.96), ALXN: 125.63 (-0.23), REGN: 393.40 (+0.85)
Portola IndexXa's Regulatory Application Validated in the EU
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 6:48AM CDT
Portola (PTLA) announced that the European Medicines Agency has accepted to review the company's Marketing Authorization Application for IndexXa.
PTLA: 20.86 (+0.50), ANIP: 61.42 (+1.68), ANIK: 47.94 (+0.70)
Portola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa(TM) (andexanet alfa), a Factor Xa Inhibitor Antidote
GlobeNewswire - Fri Aug 19, 7:30AM CDT
Portola Pharmaceuticals Inc. (NASDAQ
TLA) today announced that the MAA for IndexXa(TM) (andexanet alfa; trade name in the United States is AndexXa(TM)), a Factor Xa inhibitor antidote, has been submitted to the EMA, completed the validation period, and has been accepted for review. IndexXa is in development for patients treated with a Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding and for patients requiring urgent or emergency surgery. Portola is seeking conditional approval of IndexXa in the EU through the centralized procedure. With the acceptance of the application, the EMA's Committee for Medicinal Products for Human Use (CHMP) will now begin the centralized review procedure under a standard 210-day review period. PTLA: 20.86 (+0.50)
Portola (PTLA) Stock Down on CRL for AndexXa BLA in U.S.
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:16AM CDT
Portola (PTLA) received a Complete Response Letter for AndexXa (andexanet alfa) in the U.S.
PTLA: 20.86 (+0.50), ANIP: 61.42 (+1.68), GERN: 2.73 (+0.04), ANIK: 47.94 (+0.70)
Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa(TM) (andexanet alfa)
GlobeNewswire - Wed Aug 17, 9:56PM CDT
Portola Pharmaceuticals Inc. (NASDAQ
TLA) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for AndexXa(TM) (andexanet alfa). An FDA-designated Breakthrough Therapy, AndexXa is in development for patients treated with a direct (apixaban, rivaroxaban, or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Currently, there is no FDA-approved antidote for Factor Xa inhibitors. PTLA: 20.86 (+0.50)
Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue Aug 09, 3:07PM CDT
Portola Pharmaceuticals Inc. (NASDAQ
TLA) today provided a corporate update and reported its financial results for the quarter ended June 30, 2016. PTLA: 20.86 (+0.50)
Portola Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Tuesday, August 9
GlobeNewswire - Tue Aug 02, 3:07PM CDT
Portola Pharmaceuticals, Inc. (Nasdaq
TLA) announced today that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2016, and provide a general business overview on Tuesday, August 9, 2016, at 4:30 p.m. ET (1:30 p.m. PT). PTLA: 20.86 (+0.50)
Biotechnology Stocks on Investors' Radar -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Tue Aug 02, 9:02AM CDT
The Biotech stocks are showing substantial strength as on Monday, August 01st, 2016, the NYSE Arca Biotechnology Index was up 2.7%, reaching a seven-month intra-day high. Stock-Callers.com now assesses the following equities and see how they fared at the last close: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by downloading their comprehensive and free reports at:
TRVN: 6.77 (-0.01), PTLA: 20.86 (+0.50), ANTH: 2.91 (+0.03), NERV: 12.35 (+0.13)
Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Wed Jun 22, 7:20AM CDT
On Tuesday, June 21, 2016, the NASDAQ Composite ended the trading session at 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% to finish at 17,829.73; and the S&P 500 closed at 2,088.90, up 0.27%. The gains were broad based as five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by accessing their free trade alerts at:
TRVN: 6.77 (-0.01), PTLA: 20.86 (+0.50), ANTH: 2.91 (+0.03), NERV: 12.35 (+0.13)
Corridor Company Case Study Examines Portola Pharmaceuticals' Use of Corridor's CLM Product in Managing All Aspects of Portola's Contract Management Process
PRWeb - Wed Jun 22, 2:48AM CDT
Corridor Company, Inc., the leading provider of contract lifecycle management software powered by the SharePoint and Office 365 platforms, has published a case study about the successful deployment of its Contract Management Business Application for SharePoint, CM[.app], by Portola Pharmaceuticals, a biopharmaceutical company with a foundation of products and product candidates that significantly advances patient care in the areas of thrombosis, other hematologic disorders and inflammation. Portola's legal and finance teams now use Corridor's software to manage their entire contract lifecycle, including contract creation and request, negotiation with external parties, documented approval, and metadata reporting.
PTLA: 20.86 (+0.50)
Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Portola Pharmaceuticals Inc. (NASDAQ
TLA), today announced that it recently dosed the first patient in a Phase 2a study that is evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell and T-cell malignancies who have failed multiple therapies. Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies. PTLA: 20.86 (+0.50)
Portola Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference
GlobeNewswire - Tue May 31, 3:05PM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced that Bill Lis, chief executive officer, will present at the Goldman Sachs 37 Annual Healthcare Conference on Tuesday, June 7, 2016, at 1:20 p.m. Pacific Time in Rancho Palos Verdes, Calif. PTLA: 20.86 (+0.50)
Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
GlobeNewswire - Fri May 27, 7:45AM CDT
--Company Plans to Submit NDA and MAA for Betrixaban in Second Half of 2016--
PTLA: 20.86 (+0.50)
Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa(TM) (andexanet alfa) at International Society on Thrombosis and Haemostasis (ISTH) 2016 Scientific and Standardization Committee Meeting
GlobeNewswire - Mon May 23, 7:00AM CDT
Portola Pharmaceuticals Inc. (NASDAQ
TLA) today announced that the full data set from the Phase 3 APEX Study of betrixaban will be featured in an oral session at the 62nd Annual Scientific and Standardization Committee (SSC) Meeting of the International Society on Thrombosis and Haemostasis (ISTH), which will take place from May 25-28 in Montpellier, France. Additionally, new data from pharmacokinetic and mechanism of action studies of the Company's Factor Xa inhibitor antidote AndexXa (andexanet alfa) will be presented in poster sessions. PTLA: 20.86 (+0.50)
How are Investors Treating These Biotech? - Portola Pharma, Vitae Pharma, Anthera Pharma, and Intra-Cellular Therapies
PR Newswire - Thu May 19, 7:35AM CDT
There is no saying when exactly the Biotech space will fully recover given the relentless pressures in pricing and lack in consumer confidence. One thing is for sure in the investors circle though - numerous opportunities are up for grabs but this industry requires due-diligence. Ahead of today's session, ActiveWallSt.com's presents four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Intra-Cellular Therapies Inc. (NASDAQ: ITCI). Receive your complimentary alerts on these stocks by signing up today at:
PTLA: 20.86 (+0.50), ANTH: 2.91 (+0.03), VTAE: 6.84 (-0.07), ITCI: 40.63 (+0.29)
Portola Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Thu May 05, 3:06PM CDT
Portola Pharmaceuticals Inc. (NASDAQ
TLA), today provided a corporate update and reported its financial results for the first quarter ended March 31, 2016. PTLA: 20.86 (+0.50)
Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Thu Apr 14, 7:00AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced that new data from a pharmacokinetic modeling study designed to identify the dose of cerdulatinib for expansion cohorts in a Phase 2 study will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2016, which is taking place from April 16-20 in New Orleans. PTLA: 20.86 (+0.50)
3 Biotech Takeover Targets That Could Get Bought Soon
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 13, 2:39PM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Biotech stocks have been especially hard hit over the past six months because of concerns over drug prices, and the sell-off within the industry has resulted in bargains that big pharma might find compelling. Among...
MDVN: 80.93 (+0.37), BMRN: 95.19 (+1.30), PTLA: 20.86 (+0.50), KITE: 58.87 (+1.25), AMGN: 170.13 (+0.07), BMY: 56.76 (-0.63)
